Overview

A Prospective Double-Blind Study of Retrovir in Early HIV Infection

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerance of chronic administration of Retrovir (AZT) to adult patients with early manifestations of HIV disease. To assess the efficacy of AZT therapy in the treatment of HIV disease in these patients. (12/01/89) Information supplied by drug company update. Study discontinued due to positive data from ACTG 016.
Phase:
N/A
Details
Lead Sponsor:
Glaxo Wellcome
Treatments:
Zidovudine